A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis.
about
Tailored treatment options for patients with psoriatic arthritis and psoriasis: review of established and new biologic and small molecule therapiesPharmacological treatment of spondyloarthritis: exploring the effectiveness of nonsteroidal anti-inflammatory drugs, traditional disease-modifying antirheumatic drugs and biological therapiesMaking the next steps in psoriatic arthritis management: current status and future directionsSpanish Rheumatology Society and Hospital Pharmacy Society Consensus on recommendations for biologics optimization in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritisNew era of biologic therapeutics in atopic dermatitisTumour necrosis factor inhibitor monotherapy vs combination with MTX in the treatment of PsA: a systematic review of the literatureManaging patients with psoriatic disease: the diagnosis and pharmacologic treatment of psoriatic arthritis in patients with psoriasisPharmacogenetics of treatment response in psoriatic arthritisReview of the treatment of psoriatic arthritis with biological agents: choice of drug for initial therapy and switch therapy for non-responders.Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor.A review of the literature analyzing benefits and concerns of infliximab biosimilar CT-P13 for the treatment of rheumatologic diseases: focus on interchangeability.Psoriatic arthritis: Epidemiology, diagnosis, and treatment.Use of aspirin, non-steroidal anti-inflammatory drugs, and acetaminophen (paracetamol), and risk of psoriasis and psoriatic arthritis: a cohort studyCancer Recurrence Following Immune-Suppressive Therapies in Patients With Immune-Mediated Diseases: A Systematic Review and Meta-analysis.Patient Preferences for Treatment of Psoriasis with Biologicals: A Discrete Choice Experiment.Patient Preferences for Biologicals in Psoriasis: Top Priority of Safety for Cardiovascular Patients.Frequency of Lost to Follow-Up and Associated Factors for Patients with Rheumatic Diseases.Pain mechanisms and ultrasonic inflammatory activity as prognostic factors in patients with psoriatic arthritis: protocol for a prospective, exploratory cohort study.Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3)Clinical efficacy, radiographic and safety findings through 2 years of golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of the randomised, placebo-controlled GO-REVEAL study.Profile of ustekinumab and its potential in the treatment of active psoriatic arthritis.Glucocorticoids increase skeletal muscle NF-κB inducing kinase (NIK): links to muscle atrophy.Economic Evaluation of Timely Versus Delayed Use of Tumor Necrosis Factor Inhibitors for Treatment of Psoriatic Arthritis in the US.Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA).Real-life experience of using conventional disease-modifying anti-rheumatic drugs (DMARDs) in psoriatic arthritis (PsA). Retrospective analysis of the efficacy of methotrexate, sulfasalazine, and leflunomide in PsA in comparison to spondyloarthritidManagement of persistent inflammatory large joint monoarthritis.Effect of tumour necrosis factor blockers on radiographic progression of psoriatic arthritis: a systematic review and meta-analysis of randomised controlled trials.Psoriatic arthritis: phenotypic variance and nosology.How to translate basic knowledge into clinical application of biologic therapy in spondyloarthritis.Infliximab in psoriasis and psoriatic arthritis.Immunogenicity of anti-TNFα therapy in psoriasis: a clinical issue?Diagnosing and treating psoriatic arthritis: an update.Standards of care for patients with spondyloarthritis.Chronic inflammatory diseases: do immunological patterns drive the choice of biotechnology drugs? A critical review.Treatment of psoriatic arthritis with anti-TNF agents: a systematic review and meta-analysis of efficacy, effectiveness and safety.Novel treatments with small molecules in psoriatic arthritis.Tumour necrosis factor inhibitors in the treatment of psoriatic arthritis: a view on effectiveness, clinical practice and toxicity.Certolizumab pegol for the treatment of psoriatic arthritis.Current evidence in the field of the management with TNF-α inhibitors in psoriatic arthritis and concomitant hepatitis C virus infection.An overview of developing TNF-α targeted therapy for the treatment of psoriasis.
P2860
Q26764867-FDCC9B6A-289A-4AD5-8514-BF1EE9E2D871Q26777084-761AF685-B5CD-4F9D-B52C-07F41965C51CQ26783506-D42B6314-C65A-4AB9-B9BD-E4F27F10267CQ26852081-E73FF6F1-9D14-4816-A179-15C2724C4D00Q27001941-7116A1CD-11E9-42F3-B494-ABD4E2DF6958Q27012134-A0084D13-6613-4AB0-88E1-3CBC48DC2216Q27693878-6D2D04F8-FCC7-496B-90CE-997598B74FFCQ28081252-72B8BA78-B60F-4E35-9163-FD7454577BDAQ30399745-49BE0D1B-501D-4198-B301-AF097635FA91Q33659004-7862E022-971B-47DE-9DE2-135FB577C3C0Q33881234-2F66940D-66D6-499E-81CA-3CF31EFDAE72Q34047760-F152B8D8-F9B1-4C4C-BB9F-00C8E7DBE7ACQ34283073-4921274A-1287-4FF3-8E83-85FA47B5504EQ34520662-A4CD13C8-45CB-4811-AB0A-4BA77B5D0E69Q35658540-A212BF3E-FD2D-4562-B648-11DAA1F68540Q35860158-56BD2B20-329D-4603-B709-5EC7F0C2EECDQ35947862-A2E9F16A-029E-4FBD-B00B-2A12BD2172EEQ36819032-333F2010-90A6-43D5-8E89-F2ED1669A08BQ36968787-196B4583-4B0C-4C90-BC34-F338994DF48CQ37267600-55D42089-C75B-424D-BF90-498D162EB78FQ37301177-016CA066-7BEB-48FC-87ED-EA56FE4BFF08Q37419006-0FCA8D51-6677-4316-AA45-09576E579F6DQ37453027-F9BBD923-DAFB-4983-A44A-CFB22DECC0CCQ37465550-796D420A-3D9B-46DE-AC67-46619D60BA5EQ37679286-57D291E0-BE11-4688-83F0-9504E1ED646DQ38056418-2DD1EA45-5B26-43D1-A7A0-6088D95F4A1BQ38077142-1EC7024B-CE3C-4DCA-BD1E-1D03A0A748B3Q38078291-2B99B68E-AEF3-40AB-BB17-CE47FD4C4B3AQ38120525-C39C2305-5AD9-4310-BC64-3C60A9153E36Q38132707-DE927FA3-078B-4845-9975-F957E17F738BQ38150903-46A01F93-006B-429B-929A-76F9D34982D0Q38165235-95368044-E881-4DCC-B257-475A84E609D1Q38175872-CA967A13-42AF-4ACA-BE9B-A3B4CA1412B9Q38201788-786D3DC9-E398-4FB4-A4F7-58AEEC2C1C49Q38204241-9A900140-8F4D-47D4-A431-235C62F1A397Q38229893-082138BC-695E-4297-9927-53BB543E804EQ38264660-14A7AE9A-029E-4233-B8E0-50B9B7D59859Q38344194-F91534B1-2A47-46BA-A00F-6DAA690AECE4Q38344512-CE43E2AE-4342-4373-8CC4-01D32687E22EQ38569794-78B0DD6B-729B-470E-B6B6-0895FAA28DB4
P2860
A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
A systematic literature review ...... gement of psoriatic arthritis.
@en
A systematic literature review ...... gement of psoriatic arthritis.
@en-gb
A systematic literature review ...... gement of psoriatic arthritis.
@nl
type
label
A systematic literature review ...... gement of psoriatic arthritis.
@en
A systematic literature review ...... gement of psoriatic arthritis.
@en-gb
A systematic literature review ...... gement of psoriatic arthritis.
@nl
prefLabel
A systematic literature review ...... gement of psoriatic arthritis.
@en
A systematic literature review ...... gement of psoriatic arthritis.
@en-gb
A systematic literature review ...... gement of psoriatic arthritis.
@nl
P2093
P50
P356
P1476
A systematic literature review ...... gement of psoriatic arthritis.
@en
P2093
Cécile Gaujoux-Viala
Kevin Winthrop
Oliver FitzGerald
P304
P356
10.1136/ARD.2011.150995
P407
P50
P577
2011-07-28T00:00:00Z
P5875
P6179
1029847145